To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) is the most common cancer in the world and the leading cause of cancer deaths in Western countries. 1 More than one third of lung cancer cases are diagnosed in patients older than age 70 years, and the majority of elderly patients have metastatic disease at the time of diagnosis. 2 In these cases, a palliative treatment with single-agent gemcitabine or vinorelbine has long been considered the standard therapy on the basis of the results of ELVIS (Elderly Lung Cancer Vinorelbine Italian Study) and MILES (Multicenter Italian Lung Cancer in the Elderly Study) trials. [3] [4] [5] [6] In 2011, Quoix et al 7 compared the combination of onceper-month carboplatin and once-per-week paclitaxel versus single-agent gemcitabine or vinorelbine as first-line treatment for elderly patients with advanced NSCLC. The combination improved overall survival (OS) at the cost of higher toxicity (deaths as a result of toxicity were 4.4% v 1.3% in the two arms). Safety concerns negatively affected the use of this combination in clinical practice, notwithstanding the positive result.
Even in the era of precision medicine, excluding 15% to 20% of patients with an epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-positive tumor and another 25% to 30% with a programmed death-ligand 1(PD-L1)-positive tumor, a combination chemotherapy that includes cisplatin remains the standard treatment for the majority of adult patients with advanced NSCLC. However, there are concerns about the tolerability and feasibility of using cisplatin for elderly patients who might have an increased risk of life-threatening toxicity. [8] [9] [10] In two phase I/II studies (MILES-2P [Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non-Small-Cell Lung Cancer]), we found that the combination of cisplatin at 60 mg/m 2 with gemcitabine was feasible and worthy of a further phase III comparison.
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On these bases, we designed two randomized clinical trials,
MILES-3 (Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer) and MILES-4 (A Factorial Study of Cisplatin Added to Pemetrexed or Gemcitabine in Elderly Patients
With Nonsquamous Lung Cancer), to test whether the addition of cisplatin to single-agent chemotherapy prolongs survival of elderly patients with advanced NSCLC who do not have an EGFR mutation. 12 In the two-arm MILES-3 trial, the combination of cisplatin and gemcitabine was compared with gemcitabine alone in patients with any tumor histology. The ensuing four-arm MILES-4 trial compared gemcitabine or pemetrexed with gemcitabine plus cisplatin or pemetrexed plus cisplatin in patients with nonsquamous histology, based on the hypothesis that pemetrexed might be more effective and less toxic than gemcitabine for patients with nonsquamous histology. 13 Both trials were closed prematurely because of slow accrual, but a joint analysis allowed the researchers to properly address the main question of the addition of cisplatin according to the advice from the Independent Data Monitoring Committee.
PATIENTS AND METHODS

Eligibility Criteria
Eligible patients had previously untreated advanced NSCLC with any (MILES-3) or nonsquamous (MILES-4) histology, measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, age 70 years or older, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, life expectancy . 3 months, and adequate organ function, and they provided signed informed consent.
Key exclusion criteria were the presence of any unstable systemic disease or medical contraindication to the study medications, other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal prostate-specific antigen, symptomatic brain metastasis, or spinal cord compression not yet treated with surgery and/or radiation. Patients with activating EGFR mutations were excluded. The protocols were approved by institutional ethical committees at each participating center.
Treatment and Trial Procedures
MILES-3 and MILES-4 were open-label, multicenter, randomized phase III studies. In MILES-3, patients were randomly assigned in a 1:1 ratio to receive gemcitabine 1,200 mg/m 2 intravenously on days 1 and 8 once every 3 weeks for six cycles (standard arm) or cisplatin 60 mg/m 2 intravenously on day 1 plus gemcitabine 1,000 mg/m 2 intravenously on days 1 and 8 once every 3 weeks for six cycles (experimental arm).
MILES-4 had a factorial design and patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment arms. Patients in arm A received gemcitabine 1,200 mg/m 2 alone on days 1 and 8 once every 3 weeks for six cycles, arm B received gemcitabine 1,000 mg/m 2 on days 1 and 8 plus cisplatin 60 mg/m 2 on day 1 once every 3 weeks for six cycles, arm C received pemetrexed 500 mg/m 2 alone on day 1 once every 3 weeks for six cycles, and arm D received pemetrexed 500 mg/m 2 plus cisplatin 60 mg/m 2 on day 1 once every 3 weeks for six cycles. All the patients received oral folic acid 400 mg once per day plus an injection of vitamin B 12 1,000 mg once every 9 weeks beginning 1 to 2 weeks before the first dose of chemotherapy and continuing until 3 weeks after the last dose, and dexamethasone 4 mg twice per day for 3 days beginning on the day before chemotherapy until the day after chemotherapy. Dose reductions and delays of chemotherapy as a result of toxicity were applied as in clinical practice. The use of granulocyte colonystimulating factors was allowed as secondary prophylaxis in the case of grade 4 neutropenia. Activities of daily living (ADL) and instrumental ADL (IADL) scales were assessed at baseline.
Random assignments were performed centrally at the Clinical Trials Unit of the National Cancer Institute of Naples via a Web-based minimization procedure. In MILES-3, random assignments were stratified by center, performance status (0 v 1), tumor stage (IIIB v IV), and histotype (squamous v nonsquamous). In MILES-4 strata were center, performance status (0 v 1), tumor stage (IIIB v IV), and sex.
Outcomes
OS, defined as the time between the date of random assignment and the date of death, was the primary end point in both studies. Secondary end points in both studies included progression-free survival (PFS), objective response rate (ORR), toxicity, and quality of life (QOL). PFS was defined as the time between the date of random assignment and the date of disease progression or death, whichever occurred first. Patients who did not progress were censored on the date of the last follow-up visit.
Response was assessed by investigators according to RECIST v1.1. Patients not evaluated because of death or toxicity or refusal of treatment or loss to follow-up before the first restaging were considered nonresponders. Adverse events were coded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and toxicity was described as the worst grade suffered for each item by each patient at any time during the treatment. Global health status score of QOL was calculated at each time point by deriving the mean raw score of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire and linearly transforming it into a scale ranging from 0 to 100 in which higher values represent better function.
14 QOL response was calculated by using a 10-point threshold, previously defined as being clinically relevant.
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Statistical Analysis
The sample size in both trials was based on the primary outcome, the effect on survival of the addition of cisplatin to single-agent treatment. Both studies had an 80% power to detect a hazard ratio (HR) of death of 0.75 in favor of the combination arm. With a two-tailed alpha error of .05, 381 events were required in MILES-3 and 382 events were required in MILES-4. Planned sample size was 480 patients for MILES-3 and 550 for MILES-4 (EAST 3.1; Cytel Software, Cambridge, MA). MILES-4 also planned a second superiority comparison to assess the effect on survival of pemetrexed compared with gemcitabine. This analysis will be reported separately.
Joint efficacy and safety analyses were performed according to the intention-to-treat strategy. The analyses were performed when all the patients in both studies had completed study treatment and the planned number of events for primary analysis was reached by adding together the events reported in the two studies. No adjustment was planned for multiple comparison. All the statistical tests were interpreted as significant with a P value of less than 5%.
Median follow-up was calculated according to the Schemper's reverse Kaplan-Meier technique.
16 Survival curves were described according to the Kaplan-Meier product-limit method.
17 HR was estimated by using a stratified Cox proportional hazards model adjusted by size of center (according to tertiles of the number of enrolled patients), sex, age, PS (0 v 1), and tumor stage (IIIB v IV). Four strata were defined for the analysis according to study (MILES-3 or MILES-4): histotype (squamous or nonsquamous) and companion drug (gemcitabine or pemetrexed). A secondary analysis further introduced baseline data from geriatric ADL and IADL scales into the Cox proportional hazards model as a result of our previous findings on the significant prognostic effect of such measures in the MILES study.
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First-order interactions between treatment and the main prognostic and potentially confounding variables were tested by likelihood ratio test of two nested models with and without interaction; the effects of treatments were reported as HRs and 95% CIs for subgroup categories in a Forest plot.
Patients with at least one target or nontarget lesion at baseline according to RECIST v1.1 were eligible for response assessment. ORRs (complete plus partial) in the two arms were compared by stratified Mantel-Haenszel test, adjusted by size of center, sex, age, PS, and tumor stage and were stratified by study, histotype, and companion drug. Patients who received at least one dose of the study drug were eligible for safety assessment. All toxicity grades and severe (grade . 2) toxicities were compared between the two arms by stratified Mantel-Haenszel test.
Mean change from baseline in global health status score of QOL at each time point was compared between the two arms in a linear regression model, adjusted by the previous covariates and the baseline global health status score of QOL. QOL response was compared with x 2 test. Statistical analyses were performed using STATA MP 14.1 software (STATA, College Station, TX).
RESULTS
Patient Characteristics
Between March 31, 2011, and August 5, 2016, a total of 531 patients were enrolled in the two studies (299 in MILES-3 and 232 in MILES-4) in 46 Italian centers. Overall, 268 patients were assigned to receive monotherapy with gemcitabine or pemetrexed, and 263 were assigned to receive combination chemotherapy with gemcitabine or pemetrexed plus cisplatin (Fig 1) . All patients were included in the survival analyses. Baseline characteristics of the patients were balanced between the arms (Table 1) . Comorbidities were similarly distributed between the arms: more than half the patients had hypertension, and almost 30% had chronic obstructive pulmonary disease (Appendix Table A1 , online only). Three patients in the monotherapy arm and six patients in the combination arm withdrew consent after random assignment and never started treatment. Three patients in the monotherapy arm and six patients in the combination arm died before starting jco.org treatment. Therefore, 262 and 251 patients, respectively, were included in the compliance and safety analyses.
Treatment Compliance
The majority of patients received gemcitabine as monotherapy (78.3%) or associated with cisplatin (77.9%). The median number of treatment cycles was three (interquartile range, three to six) without cisplatin and four (interquartile range, two to six) with cisplatin. Overall, 89 patients (34.0%) treated without cisplatin and 102 patients (40.6%) treated with cisplatin completed the planned treatment. Sixteen patients (6.1%) treated without cisplatin and 30 patients (11.7%) treated with cisplatin stopped treatment as a result of toxicity or refusal of treatment (Appendix Table A2 , online only). Information on second-line treatment after disease progression was reported in 186 patients (35.0%) with no differences between treatment arms (Appendix Table A3 , online only)
Primary Analysis
Data from the two studies were locked and combined on November 22, 2016, with a median follow-up of 24 months. Overall, 384 deaths were recorded (200 in the monotherapy arm and 184 in the combination arm). HR was 0.86 (95% CI, 0.70 to 1.05; P = .14), and median OS was 7.5 months (95% CI, 6.2 to 9.5 months) in the monotherapy arm and 9.6 months (95% CI, 8.1 to 11.7 months) in the combination arm (Fig 2A) . Similar results (HR 0.96; 95% CI, 0.74 to 1.15; P = .48) were observed when ADL and IADL scores were added to the model (447 patients and 328 deaths were available). No statistically significant interaction was found between treatment effect (HR of death) and the main prognostic and potentially confounding variables (Fig 3) .
Secondary Analyses
For PFS analyses, the total number of events was 448: 232 in the monotherapy arm and 216 in the combination arm. HR was 0.76 (95% CI, 0.63 to 0.92; P = .006), and median PFS was 3.0 months (95% CI, 2.5 to 3.8 months) in the monotherapy arm and 4.6 months (95% CI, 4.1 to 5.3 months) in the combination arm (Fig 2B) . In addition, the analysis accounting for ADL and IADL scores as covariates produced similar results (HR, 0.78; 95% CI, 0.63 to 0.96; P = .02).
According to RECIST v1.1, 22 of 260 eligible patients achieved an ORR of 8.5% (95% CI, 5.4% to 12.5%) in the monotherapy arm, and 38 of 246 achieved an ORR of 15.5% (95% CI, 11.2 to 20.6) in the combination arm (P = .02; Appendix Table A4 , online only).
Patients receiving the cisplatin combination experienced significantly more hematologic and neurologic toxicity, mucositis, nausea, and vomiting and significantly more severe thrombocytopenia, leucopenia, neutropenia, febrile neutropenia, fatigue, and anorexia (see Appendix Tables 2 and A5 [online only] for complete information). Significantly more fever and an increase in ALT and AST were reported with monotherapy. There were three (1.1%) deaths as a result of toxicity with monotherapy and 2 (0.7%) with the cisplatin combination.
Global health status score of QOL after cycles 1 and 2 was not improved in patients receiving cisplatin (Fig 4) . Improvement of at least 10 points in QOL was reported in 77 (39.3%) of 197 patients without cisplatin and 61 (37.2%) of 164 patients with cisplatin (P = .80).
DISCUSSION
The joint analysis of MILES-3 and MILES-4 trials shows that the addition of cisplatin to single-agent chemotherapy for elderly patients with advanced NSCLC does not significantly prolong OS and does not improve global health status score of QOL. Therefore, combination chemotherapy that includes cisplatin should no longer be proposed in this clinical setting.
This study has several strengths that increase the generalizability of its findings. First, it is the largest trial devoted to test the addition of a platinum compound to single-agent chemotherapy in elderly patients with NSCLC. Second, drugs used in the control arm are recognized worldwide as standard treatments. Third, the experimental platinum-based combination was properly selected through the phase II MILES-2P studies. In those trials, 60 mg/m 2 of cisplatin could be added to gemcitabine but only 40 mg/m 2 could be added to vinorelbine, jco.org the probability that the combination would significantly prolong survival was , 1%. The experimental treatment was significantly more toxic, particularly for neutropenia and asthenia, with a 4.4% incidence of death as a result of toxicity (compared with 1.3% in the control arm). This was probably a result of the high drug doses in the combination arm and of including patients with adverse clinical conditions (PS 2) in the trial. Nevertheless, there was a statistically significant prolongation of OS (median, 6.2 v 10.3 months; HR, 0.64) and PFS and an improvement in response rate, although there was no difference in global health status score of QOL.
7 MILES-3 and MILES-4 results are consistent with Japanese negative data on the addition of cisplatin to single-agent chemotherapy, and they actually represent the first evidence coming from a trial with a control arm that was considered a standard worldwide. Acknowledging the limitations of indirect comparisons, it seems that the addition of carboplatin yielded better results than the addition of cisplatin, although the evidence comes from only one trial, the IFCT-0501, in which toxicity was relevant; caution is required when generalizing these results to clinical practice.
The major weakness of the MILES-3 and MILES-4 studies derives from the slow enrollment and the need to join the two trials to reach the sample size required to assess the efficacy of cisplatin. We managed this issue using stratification by all the constitutive differences in inclusion criteria and treatment plan between the With cisplatintwo trials. In addition, the two trials were conducted during the same timeframe, by the same cooperative group, with similar protocol rules, the same coordination unit, and the same data management system, suggesting that heterogeneity in the conduct of the two studies is limited and might not have any effect on the final result. Thanks to the availability of new drugs targeting immune checkpoints and molecular alterations, it might seem that optimization of chemotherapy is no longer an important issue. However, according to the currently available drugs for patients with advanced NSCLC, those eligible for treatment with tyrosine kinase inhibitors represent a small proportion of patients because of the relative rarity of EGFR, ALK, and the molecular defects of reactive oxygen species. Conversely, immunotherapy is available as a single drug in first-line therapy for patients selected on the basis of PD-L1 expression, and its use as second-line therapy, independent of PD-L1 expression, is planned after chemotherapy. Antiangiogenic drugs are always used in combination with chemotherapy. Overall, we estimate that approximately 80% of patients with advanced NSCLC still receive chemotherapy during their lifetime: approximately 60% as first-line and 40% as secondline treatment. Therefore, we believe that refining chemotherapy, particularly for the elderly population, in which its toxicity may actually prevent the use of more recent and innovative treatment options in some cases, is important.
In conclusion, the addition of cisplatin to single-agent chemotherapy does not significantly prolong OS nor does it improve global health status score of QOL of elderly patients with advanced NSCLC. It should no longer be among the preferred options for first-line treatment in clinical practice. This result fully supports the treatment algorithm proposed for elderly patients in the European Society of Medical Oncology guidelines. 20 Standard treatment should remain single-agent chemotherapy whereas carboplatin-based combinations might be considered as an alternative in selected cases, with caution regarding potential toxicity. 17:343-346, 1996 17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 1958 18. Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 23: [6865] [6866] [6867] [6868] [6869] [6870] [6871] [6872] 2005 19. Abe T, Takeda K, Ohe Y, et al: Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The intergroup trial JCOG0803/WJOG4307L. J Clin Oncol 33: [575] [576] [577] [578] [579] [580] [581] 2015 Statistical analysis: Ciro Gallo (head), Paolo Chiodini, Simona Signoriello, and Giuseppe Signoriello (Campania University Luigi Vanvitelli, Napoli). EGFR TKI  29  35  64  Docetaxel  18  28  46  Vinorelbine  19  3  22  Pemetrexed  10  6  16  Platinum-based chemotherapy  9  4  13  Nivolumab  5  7  12  Gemcitabine  3  5  8  ALK TKI  1  4  5  Total  94  92  186 Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. 
